While there are many drugs and medical devices for treating cardiovascular diseases, including heart disease, there are still many patients worldwide with unmet needs. In the United States, total medical costs for heart failure with preserved ejection fraction (HFpEF) alone are roughly $94B annually, which equates to roughly $44K per patient per year diagnosed with HFpEF.1
At Astellas Rx+, our goal is to contribute to helping heart failure patients by developing cutting-edge medical technologies. Z1608 is one tool currently in development. Z1608 is comprised of a medical device, a SaMD digital therapeutic, and a clinical review team. Building on the strengths of our partners, we will leverage Welldoc’s digital therapeutic capabilities, Eko Health’s latest digital stethoscope plus cloud-based analysis software with the addition of a clinical review team with the goal of:
- Improving disease management and aiming to positively impact clinical outcomes for patients
- Providing healthcare providers with an innovative tool for managing heart failure
- Supporting clinical review and evaluation through Z1608's dedicated clinical team
- Studying whether Z1608 can reduce acute decompensation of heart failure through behavior change and early intervention
- Reducing total cost of care to payers
Astellas Rx+ is targeting initial commercial programs launching in the United States in 2024.
Source: 1Truven MarketScan data from Jan 1, 2018 to Dec 31, 2020 used to calculate annual estimates